Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Spindler

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Acta Oncologica (Stockholm, Sweden)|August 14, 2020
Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancerAnders K Boysen, Niels Pallisgaard, Christina S A Andersen, et al.
BMC Cancer|March 29, 2011
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancerKaren-Lise G Spindler, Niels Pallisgaard, Jan Lindebjerg, et al.
Anticancer Research|February 11, 2014
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research studyKaren-Lise G Spindler, Niels Pallisgaard, Rikke F Andersen, et al.
Acta Oncologica (Stockholm, Sweden)|September 14, 2007
Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancerKaren-Lise G Spindler, Jens N Nielsen, Dorthe Ornskov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2009
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancerK-L G Spindler, R F Andersen, L H Jensen, et al.
British Journal of Cancer|November 16, 2013
The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLCA D Nygaard, P C Holdgaard, K-L G Spindler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 18, 2025
Response to "Optimizing radiotherapy for anal cancer: A call for sub-structure based dose constraints"Katrine S Storm, Karen Lise G Spindler, Gitte F Persson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 6, 2025
Lower urinary tract sub-structures as predictors of late urinary toxicity in concurrent chemo-radiotherapy for anal cancerKatrine S Storm, Karen Lise G Spindler, Gitte F Persson, et al.
International Journal of Colorectal Disease|December 2, 2025
Longitudinal assessment of quality of life and symptom burden in locally advanced rectal cancer patients receiving IMRT-based preoperative radiotherapy: A prospective cohort studyChristina G Truelsen, Camilla S Kronborg, Anne Ramlov, et al.
Journal of Hepatology|January 1, 1997
Long-term expression of the hepatitis B virus core-e- and X-proteins does not cause pathologic changes in transgenic miceK Reifenberg, J Löhler, H P Pudollek, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Acta Oncologica (Stockholm, Sweden)|August 14, 2020
Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancerAnders K Boysen, Niels Pallisgaard, Christina S A Andersen, et al.
BMC Cancer|March 29, 2011
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancerKaren-Lise G Spindler, Niels Pallisgaard, Jan Lindebjerg, et al.
Anticancer Research|February 11, 2014
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research studyKaren-Lise G Spindler, Niels Pallisgaard, Rikke F Andersen, et al.
Acta Oncologica (Stockholm, Sweden)|September 14, 2007
Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancerKaren-Lise G Spindler, Jens N Nielsen, Dorthe Ornskov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2009
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancerK-L G Spindler, R F Andersen, L H Jensen, et al.
British Journal of Cancer|November 16, 2013
The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLCA D Nygaard, P C Holdgaard, K-L G Spindler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 18, 2025
Response to "Optimizing radiotherapy for anal cancer: A call for sub-structure based dose constraints"Katrine S Storm, Karen Lise G Spindler, Gitte F Persson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 6, 2025
Lower urinary tract sub-structures as predictors of late urinary toxicity in concurrent chemo-radiotherapy for anal cancerKatrine S Storm, Karen Lise G Spindler, Gitte F Persson, et al.
International Journal of Colorectal Disease|December 2, 2025
Longitudinal assessment of quality of life and symptom burden in locally advanced rectal cancer patients receiving IMRT-based preoperative radiotherapy: A prospective cohort studyChristina G Truelsen, Camilla S Kronborg, Anne Ramlov, et al.
Journal of Hepatology|January 1, 1997
Long-term expression of the hepatitis B virus core-e- and X-proteins does not cause pathologic changes in transgenic miceK Reifenberg, J Löhler, H P Pudollek, et al.
Pageof 5